These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16098293)

  • 41. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.
    Estorch M; Carrió I; Berná L; Martínez-Duncker C; Alonso C; Germá JR; Ojeda B
    J Nucl Med; 1990 Dec; 31(12):1965-9. PubMed ID: 2266394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography.
    Elbl L; Hrstkova H; Chaloupka V; Novotny J; Michalek J
    Neoplasma; 2003; 50(3):191-7. PubMed ID: 12937852
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
    Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
    N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Selective toxicity of cytostatic agents: studies on the cardiotoxicity of doxorubicin, its pathogenesis and contraindications].
    Lenzhofer R
    Wien Klin Wochenschr Suppl; 1983; 144():3-31. PubMed ID: 6198807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
    Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
    J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Evaluation of adriamycin cardiotoxicity using equilibrium radionuclide ventriculography. II. Results during exercise].
    Knesewitsch P; Göldel NH; Fritsch S; Moser E
    Nuklearmedizin; 1987 Oct; 26(5):212-9. PubMed ID: 3432065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiblastic drug-induced cardiotoxicity and cardioprotection: a compendium.
    Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S1-2. PubMed ID: 27183519
    [No Abstract]   [Full Text] [Related]  

  • 48. Doxorubicin cardiotoxicity in children.
    Biancaniello T; Meyer RA; Wong KY; Sager C; Kaplan S
    J Pediatr; 1980 Jul; 97(1):45-50. PubMed ID: 7381647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.
    Ewer MS; Ali MK; Mackay B; Wallace S; Valdivieso M; Legha SS; Benjamin RS; Haynie TP
    J Clin Oncol; 1984 Feb; 2(2):112-7. PubMed ID: 6699662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiac gallium uptake in doxorubicin-induced cardiotoxicity.
    Hatfield MK; Martin WB; Ryan JW; Vokes EE; Vogelzang NJ
    Clin Nucl Med; 1986 Nov; 11(11):756-7. PubMed ID: 3791781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases.
    Saini J; Rich MW; Lyss AP
    Ann Intern Med; 1987 Jun; 106(6):814-6. PubMed ID: 3579067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serial assessment of doxorubicin cardiotoxicity in pediatric patients with quantitative radionuclide angiocardiography.
    Moodie DS; Dyment PG; Napoli C; Cook SA
    Cleve Clin Q; 1980; 47(4):327-31. PubMed ID: 7471466
    [No Abstract]   [Full Text] [Related]  

  • 53. Radionucleotide ejection fraction and prediction of doxorubicin cardiotoxicity.
    Morgan GW; Choy D; Freedman A
    Lancet; 1978 Jun; 1(8077):1315-6. PubMed ID: 78081
    [No Abstract]   [Full Text] [Related]  

  • 54. Doxorubicin cardiotoxicity.
    Unverferth DV; Magorien RD; Leier CV; Balcerzak SP
    Cancer Treat Rev; 1982 Jun; 9(2):149-64. PubMed ID: 6751530
    [No Abstract]   [Full Text] [Related]  

  • 55. Bradycardia associated with pegylated liposomal doxorubicin administration: a case report.
    Xie Z; Wu W; Xing H; Cai Y; Wang X; Chen J
    Eur J Hosp Pharm; 2017 Mar; 24(2):128-130. PubMed ID: 31156919
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A quantitative systems pharmacology approach to predict the safe-equivalent dose of doxorubicin in patients with cardiovascular comorbidity.
    Sang L; Yuan Y; Zhou Y; Zhou Z; Jiang M; Liu X; Hao K; He H
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1512-1524. PubMed ID: 34596967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
    Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
    J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
    Villani F; Meazza R; Materazzo C
    Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review of tests for monitoring doxorubicin-induced cardiomyopathy.
    Ganz WI; Sridhar KS; Ganz SS; Gonzalez R; Chakko S; Serafini A
    Oncology; 1996; 53(6):461-70. PubMed ID: 8960141
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.